2seventy bio, Inc. (TSVT) Tops Q3 EPS by 36c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
November 14, 2023 7:00 AM ESTAbecma (idecabtagene vicleucel) data to be presented at ASH 2023; multiple new analyses of KarMMa-3 and KarMMa-2c add to growing body of data supporting the potential safety and efficacy of Abecma in earlier lines of treatment
Abecma generated $69 million U.S. commercial revenue in the third quarter of 2023; $302 million U.S. commercial revenue year-to-date
Two solid tumor programs positioned to enter clinical trials in 2024
Ended quarter with $284.3 million cash, cash equivalents, and marketable securities
Conference call today at 8:00... More
